Teva Loses Decision on Validity of Third Copaxone Patent
- Mylan, Amneal win patent office ruling on Teva’s MS drug
- Two other patents were already deemed invalid by U.S. agency
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated Thursday by a U.S. agency, a further blow to its bid to block generic versions of a drug that accounts for 20 percent of its revenue.
The Patent Trial and Appeal Board sided with Mylan NV and Amneal Pharmaceuticals LLC in ruling that the patent covering the drug’s thrice-weekly dosage never should have been issued. Teva’s next step is to ask the board to reconsider that decision, and to petition an appeals court that specializes in patent law.